WO1998057621A1 - Modulation angiogenique par transduction du signal de notch - Google Patents

Modulation angiogenique par transduction du signal de notch Download PDF

Info

Publication number
WO1998057621A1
WO1998057621A1 PCT/US1998/013050 US9813050W WO9857621A1 WO 1998057621 A1 WO1998057621 A1 WO 1998057621A1 US 9813050 W US9813050 W US 9813050W WO 9857621 A1 WO9857621 A1 WO 9857621A1
Authority
WO
WIPO (PCT)
Prior art keywords
notch4
protein
cells
ligand
notch4 protein
Prior art date
Application number
PCT/US1998/013050
Other languages
English (en)
Inventor
Jan Kitajewski
Hendrik Uyttendaele
Original Assignee
The Trustees Of Columbia University In The City Ofnew York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Ofnew York filed Critical The Trustees Of Columbia University In The City Ofnew York
Priority to AU81628/98A priority Critical patent/AU8162898A/en
Publication of WO1998057621A1 publication Critical patent/WO1998057621A1/fr
Priority to US09/467,997 priority patent/US6379925B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention porte sur des procédés de modulation de l'angiogenèse consistant à activer ou inhiber l'angiogenèse, par exemple, en association avec un traitement des anomalies telles que des hémangiomes, des hémangiosarcomes, le sarcome de Kaposi, les troubles ischémiques et les blessures. Ces procédés consistent à administrer des composés qui sont des agonistes ou des antagonistes sélectifs de la protéine Notch4. Cette invention porte également sur une molécule d'acide nucléique isolée codant une Notch4, une protéine Notch4 isolée, des vecteurs comprenant une molécule d'acide nucléique isolée codant une protéine Notch4, des cellules comprenant ces vecteurs, des anticorps dirigés contre la protéine Notch4, des sondes d'acide nucléique utilisées dans la détection des acides nucléiques codant la protéine Notch4 et des oligonucléotides antisens complémentaires à des séquences uniques quelconques d'une molécule d'acide nucléique qui code la protéine Notch4.
PCT/US1998/013050 1997-06-18 1998-06-18 Modulation angiogenique par transduction du signal de notch WO1998057621A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU81628/98A AU8162898A (en) 1997-06-18 1998-06-18 Angiogenic modulation by notch signal transduction
US09/467,997 US6379925B1 (en) 1997-06-18 1999-12-20 Angiogenic modulation by notch signal transduction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87835197A 1997-06-18 1997-06-18
US08/878,351 1997-06-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US87835197A Continuation-In-Part 1997-06-18 1997-06-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/467,997 Continuation US6379925B1 (en) 1997-06-18 1999-12-20 Angiogenic modulation by notch signal transduction

Publications (1)

Publication Number Publication Date
WO1998057621A1 true WO1998057621A1 (fr) 1998-12-23

Family

ID=25371857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/013050 WO1998057621A1 (fr) 1997-06-18 1998-06-18 Modulation angiogenique par transduction du signal de notch

Country Status (2)

Country Link
AU (1) AU8162898A (fr)
WO (1) WO1998057621A1 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073329A2 (fr) * 1999-05-26 2000-12-07 The Victoria University Of Manchester Utilisation de gènes du type notch
WO2001092571A1 (fr) * 2000-05-31 2001-12-06 Schizophrenia Association Of Great Britain Gene notch 4 et schizophrenie
WO2002012447A3 (fr) * 2000-08-03 2003-04-24 Univ Michigan Isolement et utilisation de cellules souches de tumeurs solides
WO2004035676A2 (fr) * 2002-10-16 2004-04-29 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression homologue 4 notch (drosophile)
EP1461023A2 (fr) * 2001-12-07 2004-09-29 The Regents Of The University Of Michigan Identification et caracterisation prospectives des cellules souches cancereuses du sein
WO2006085224A2 (fr) * 2005-02-07 2006-08-17 Karolinska Innovations Ab Modulation de reponses a l'hypoxie par la voie de signalisation notch
WO2008108910A2 (fr) * 2007-03-05 2008-09-12 Board Of Regents, The University Of Texas System Régulation génétique négative de la régénération des cellules cancéreuses en synergie avec une immunothérapie notch ou numb spécifique
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
JP2010214019A (ja) * 2009-03-18 2010-09-30 Chiba Univ ノッチシグナルを利用した虚血組織再生方法
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
AU2008200135B2 (en) * 2000-08-03 2012-06-14 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8226943B2 (en) 2008-07-08 2012-07-24 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
US8324361B2 (en) 2005-10-31 2012-12-04 Oncomed Pharmaceuticals, Inc. Nucleic acid molecules encoding soluble frizzled (FZD) receptors
US8507442B2 (en) 2008-09-26 2013-08-13 Oncomed Pharmaceuticals, Inc. Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US9157904B2 (en) 2010-01-12 2015-10-13 Oncomed Pharmaceuticals, Inc. Wnt antagonists and methods of treatment and screening
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
US9850311B2 (en) 2005-10-31 2017-12-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US11046760B2 (en) 2014-10-31 2021-06-29 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
WO2024074649A1 (fr) * 2022-10-05 2024-04-11 Alcea Therapeutics, Inc. Anticorps notch4, compositions et procédés de traitement d'une inflammation des voies respiratoires

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JARRLAULT S., ET AL.: "SIGNALLING DOWNSTREAM OF ACTIVATED MAMMALIAN NOTCH.", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 377., 28 September 1995 (1995-09-28), United Kingdom, pages 355 - 358., XP002913175, ISSN: 0028-0836, DOI: 10.1038/377355a0 *
LINDSELL C. E., ET AL.: "JAGGED: A MAMMALIAN LIGAND THAT ACTIVATES NOTCH1.", CELL, CELL PRESS, US, vol. 80., 24 March 1995 (1995-03-24), US, pages 909 - 917., XP002913173, ISSN: 0092-8674, DOI: 10.1016/0092-8674(95)90294-5 *
ROBBINS J., ET AL.: "MOUSE MAMMARY TUMOR GENE INT-3: A MEMBER OF THE NOTCH GENE FAMILY TRANSFORMS MAMMARY EPITHELIAL CELLS.", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 66., no. 04., 1 April 1992 (1992-04-01), US, pages 2594 - 2599., XP002913176, ISSN: 0022-538X *
SUGAYA K., ET AL.: "GENE ORGANIZATION OF HUMAN NOTCH4 AND (CTG)NU POLYMORPHISM IN THIS HUMAN COUNTERPART GENE OF MOUSE PROTO-ONCOGENE INT3.", GENE., ELSEVIER, AMSTERDAM., NL, vol. 189., no. 02., 21 April 1997 (1997-04-21), NL, pages 235 - 244., XP002913172, ISSN: 0378-1119, DOI: 10.1016/S0378-1119(96)00857-8 *
SUGAYA K., ET AL.: "THREE GENES IN THE HUMAN MHC CLASS III REGION NEAR THE JUNCTION WITH THE CLASS II: GENE FOR RECEPTOR OF ADVANCED GLYCOSYLATION END PRODUCTS, PBX2 HOMEOBOX GENE AND A NOTCH HOMOLOG, HUMAN COUNTERPARTOF MOUSE MAMMARY TUMOR GENE INT-3.", GENOMICS, ACADEMIC PRESS, SAN DIEGO., US, vol. 23., no. 02., 15 September 1994 (1994-09-15), US, pages 408 - 419., XP002913171, ISSN: 0888-7543, DOI: 10.1006/geno.1994.1517 *
UYTTENDAELE H., ET AL.: "NOTCH4/INT-3, A MAMMARY PROTO-ONCOGENE, IS AN ENDOTHELIAL CELL- SPECIFIC MAMMALIAN NOTCH GENE.", DEVELOPMENT, THE COMPANY OF BIOLOGISTS LTD., GB, vol. 122., no. 07., 1 July 1996 (1996-07-01), GB, pages 2251 - 2259., XP002913170, ISSN: 0950-1991 *
ZIMRIN A. B., ET AL.: "AN ANTISENSE OLIGONUCLEOTIDE TO THE NOTCH LIGAND JAGGED ENHANCES FIBROLAST GROWTH FACTOR-INDUCED ANGIOGENESIS IN VITRO*.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 271., no. 51., 20 December 1996 (1996-12-20), US, pages 32499 - 32502., XP002913174, ISSN: 0021-9258, DOI: 10.1074/jbc.271.51.32499 *

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073329A3 (fr) * 1999-05-26 2001-02-22 Univ Manchester Utilisation de gènes du type notch
WO2000073329A2 (fr) * 1999-05-26 2000-12-07 The Victoria University Of Manchester Utilisation de gènes du type notch
WO2001092571A1 (fr) * 2000-05-31 2001-12-06 Schizophrenia Association Of Great Britain Gene notch 4 et schizophrenie
US7115360B2 (en) 2000-08-03 2006-10-03 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2002012447A3 (fr) * 2000-08-03 2003-04-24 Univ Michigan Isolement et utilisation de cellules souches de tumeurs solides
AU2008200133B2 (en) * 2000-08-03 2012-06-14 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
AU2008200135B2 (en) * 2000-08-03 2012-06-14 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
EP2359863A3 (fr) * 2000-08-03 2012-08-15 The Regents Of The University Of Michigan Isolation et utilisation de cellules souches de tumeur solide
US7754206B2 (en) 2000-08-03 2010-07-13 The Regents Of The University Of Michigan Method for treating cancer using a Notch4 ligand antagonist
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US9089556B2 (en) 2000-08-03 2015-07-28 The Regents Of The University Of Michigan Method for treating cancer using an antibody that inhibits notch4 signaling
US9492538B2 (en) 2000-08-03 2016-11-15 The Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
EP1461023A2 (fr) * 2001-12-07 2004-09-29 The Regents Of The University Of Michigan Identification et caracterisation prospectives des cellules souches cancereuses du sein
EP1461023A4 (fr) * 2001-12-07 2005-08-31 Univ Michigan Identification et caracterisation prospectives des cellules souches cancereuses du sein
EP1567009A4 (fr) * 2002-10-16 2006-05-03 Isis Pharmaceuticals Inc Modulation antisens de l'expression homologue 4 notch (drosophile)
EP1567009A2 (fr) * 2002-10-16 2005-08-31 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression homologue 4 notch (drosophile)
WO2004035676A3 (fr) * 2002-10-16 2005-04-14 Isis Pharmaceuticals Inc Modulation antisens de l'expression homologue 4 notch (drosophile)
WO2004035676A2 (fr) * 2002-10-16 2004-04-29 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression homologue 4 notch (drosophile)
WO2006085224A3 (fr) * 2005-02-07 2006-11-23 Karolinska Innovations Ab Modulation de reponses a l'hypoxie par la voie de signalisation notch
WO2006085224A2 (fr) * 2005-02-07 2006-08-17 Karolinska Innovations Ab Modulation de reponses a l'hypoxie par la voie de signalisation notch
US8324361B2 (en) 2005-10-31 2012-12-04 Oncomed Pharmaceuticals, Inc. Nucleic acid molecules encoding soluble frizzled (FZD) receptors
US9850311B2 (en) 2005-10-31 2017-12-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9228013B2 (en) 2005-10-31 2016-01-05 OncoMed Pharmaceuticals Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell
US8765913B2 (en) 2005-10-31 2014-07-01 Oncomed Pharmaceuticals, Inc. Human frizzled (FZD) receptor polypeptides and methods of use thereof for treating cancer and inhibiting growth of tumor cells
US9732139B2 (en) 2005-10-31 2017-08-15 Oncomed Pharmaceuticals, Inc. Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
US8206713B2 (en) 2006-06-13 2012-06-26 Oncomed Pharmaceuticals, Inc. Method of treating cancer using antibodies to a non-ligand binding region of NOTCH2
US9676865B2 (en) 2006-06-13 2017-06-13 Oncomed Pharmaceuticals, Inc. Antibodies to a non-ligand binding region of at least two NOTCH receptors
US8784811B2 (en) 2006-06-13 2014-07-22 Oncomed Pharmaceuticals, Inc. Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1
US8404237B2 (en) 2006-06-13 2013-03-26 OncoMed Pharamaceuticals, Inc. Antibodies to the NOTCH1 receptor
US9228020B2 (en) 2006-09-29 2016-01-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
US9376497B2 (en) 2006-09-29 2016-06-28 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8460661B2 (en) 2007-01-24 2013-06-11 Oncomed Pharmaceuticals, Inc. Methods of using antibodies that bind the glutamate ligand binding region of Notch1
US8921106B2 (en) 2007-01-24 2014-12-30 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of NOTCH3
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
US9617340B2 (en) 2007-01-24 2017-04-11 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008108910A3 (fr) * 2007-03-05 2008-11-20 Univ Texas Régulation génétique négative de la régénération des cellules cancéreuses en synergie avec une immunothérapie notch ou numb spécifique
WO2008108910A2 (fr) * 2007-03-05 2008-09-12 Board Of Regents, The University Of Texas System Régulation génétique négative de la régénération des cellules cancéreuses en synergie avec une immunothérapie notch ou numb spécifique
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8226943B2 (en) 2008-07-08 2012-07-24 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
US8945873B2 (en) 2008-07-08 2015-02-03 Oncomed Pharmaceuticals, Inc. Polynucleotides encoding Notch receptor antibodies
US8945874B2 (en) 2008-07-08 2015-02-03 Oncomed Pharmaceuticals, Inc. Polynucleotides encoding NOTCH1 receptor antibodies
US8435513B2 (en) 2008-07-08 2013-05-07 Oncomed Pharmaceuticals, Inc. NOTCH1 receptor antibodies and methods of treatment
US8980260B2 (en) 2008-07-08 2015-03-17 Oncomed Pharmaceuticals, Inc. Monoclonal antibody that binds human notch2 and notch3
US8945547B2 (en) 2008-07-08 2015-02-03 Oncomed Pharmaceuticals, Inc. Notch1 receptor antibodies and methods of treatment
US9499613B2 (en) 2008-07-08 2016-11-22 Oncomed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
US8425903B2 (en) 2008-07-08 2013-04-23 Oncomed Pharmaceuticals, Inc. Methods of treatment by administering antibodies to notch receptors
US9505832B2 (en) 2008-07-08 2016-11-29 Oncomed Pharmaceuticals, Inc. Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3
US9573998B2 (en) 2008-09-26 2017-02-21 Oncomed Pharmaceuticals, Inc. Antibodies against human FZD5 and FZD8
US8507442B2 (en) 2008-09-26 2013-08-13 Oncomed Pharmaceuticals, Inc. Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
US9273139B2 (en) 2008-09-26 2016-03-01 Oncomed Pharmaceuticals, Inc. Monoclonal antibodies against frizzled
US8975044B2 (en) 2008-09-26 2015-03-10 Oncomed Pharmaceuticals, Inc. Polynucleotides encoding for frizzled-binding agents and uses thereof
JP2010214019A (ja) * 2009-03-18 2010-09-30 Chiba Univ ノッチシグナルを利用した虚血組織再生方法
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
US9511139B2 (en) 2009-10-16 2016-12-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent
US10870693B2 (en) 2009-10-16 2020-12-22 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent
US9982042B2 (en) 2009-10-16 2018-05-29 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent
US9579361B2 (en) 2010-01-12 2017-02-28 Oncomed Pharmaceuticals, Inc. Wnt antagonist and methods of treatment and screening
US9157904B2 (en) 2010-01-12 2015-10-13 Oncomed Pharmaceuticals, Inc. Wnt antagonists and methods of treatment and screening
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
US9499630B2 (en) 2010-04-01 2016-11-22 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9480744B2 (en) 2010-09-10 2016-11-01 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US10730940B2 (en) 2011-09-23 2020-08-04 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
US9376488B2 (en) 2011-09-23 2016-06-28 Oncomed Pharmaceuticals, Inc. VEGF binding antibodies
US9574009B2 (en) 2011-09-23 2017-02-21 Oncomed Pharmaceuticals, Inc. Polynucleotides encoding VEGF/DLL4 binding agents
US9879084B2 (en) 2011-09-23 2018-01-30 Oncomed Pharmaceuticals, Inc. Modified immunoglobulin molecules that specifically bind human VEGF and DLL4
US11512128B2 (en) 2011-09-23 2022-11-29 Mereo Biopharma 5, Inc. VEGF/DLL4 binding agents and uses thereof
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
US9987357B2 (en) 2013-02-04 2018-06-05 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a WNT pathway inhibitor
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US11046760B2 (en) 2014-10-31 2021-06-29 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
WO2024074649A1 (fr) * 2022-10-05 2024-04-11 Alcea Therapeutics, Inc. Anticorps notch4, compositions et procédés de traitement d'une inflammation des voies respiratoires

Also Published As

Publication number Publication date
AU8162898A (en) 1999-01-04

Similar Documents

Publication Publication Date Title
US6379925B1 (en) Angiogenic modulation by notch signal transduction
WO1998057621A1 (fr) Modulation angiogenique par transduction du signal de notch
Uyttendaele et al. Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene
Letsou et al. Drosophila Dpp signaling is mediated by the punt gene product: a dual ligand-binding type II receptor of the TGFβ receptor family
EP1072273B1 (fr) Inhibiteurs de vascularisation
JPH06506598A (ja) 副甲状腺ホルモンのレセプターとそれをコードしているｄｎａ
PL182324B1 (pl) Sekwencja polinukleotydowa kodujaca bialko ludzkiej protokadheryny pc3, wektor zawierajacy te sekwencje, komórka gospodarza transfekowana wektorem, bialko i sposób wytwarzania ludzkiej protokadheryny pc3 i przeciwcialo przeciwko ludzkiej pc3 PL
US20020147329A1 (en) Method of modulating tissue growth using Frzb protein
WO1996040769A1 (fr) Locus-1 de cellules endotheliales a developpement regule
JP2003524387A (ja) 分泌及び膜貫通ポリペプチドとそれをコードする核酸
BG64779B1 (bg) Лиганд сроден с тумор некрозис фактор
CA2299619A1 (fr) Nouveau recepteur orphelin
US20060241284A1 (en) Transmembrane protein amigo and uses thereof
JP2002536997A (ja) 新規なｇ蛋白質結合受容体の１４２７３受容体
JP4960091B2 (ja) 新規抗血管新生剤及びその使用、特には癌の治療における使用
US6432410B1 (en) Morphogenic proteins
US20030009023A1 (en) Isolation and method of using tissue growth-inducing Frzb protein
WO1999026980A1 (fr) Reactifs et procedes d'utilisation de proteines de la famille sap, nouveaux regulateurs de transduction de signaux
US20040126819A1 (en) Glial cell line-derived neurotrophic factor receptors
KR20010012826A (ko) 신경교 세포주-유래 향신경성 인자 수용체
JP4357003B2 (ja) 形態形成タンパク質
JP2001505420A (ja) 肝臓アクチビン／インヒビンのヌクレオチド配列およびタンパク質配列ならびにそれらに基づく方法
EP0939814A1 (fr) Proteines "fringe" et signalisation de notch
Kitajewski et al. Role of the Int-3 Oncogene in Mammary Gland Development and Tumorigenesis.
CA2319208A1 (fr) Recepteurs orphelins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09467997

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999504989

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase